VJOncology Podcast

Latest Episodes:

Updates in cervical cancer Jan 20, 2023

Show notes

January is Cervical Cancer Awareness month, so for this podcast, we’ve collected the latest updates from our interviews with leading experts in cervical cancer.

Dr Jamie Takayesu, MD, of the University of Michigan, Ann Arbor, MI, explains recent research into disparities in the assessment of sexual function of men and women undergoing radiotherapy for prostate cancer or cervical cancer. Professor Jyoti Mayadev, MD, of the University of California San Diego, San Diego, CA, takes us through the Phase III CALLA trial, which investigated durvalumab and chemoradiotherapy for cervical cancer. Finally, Dr Kamran Ahmed, MD, of Moffitt Cancer Center, Tampa, FL, explains interim results from a Phase II trial of atezolizumab and SBRT in advanced cervical cancer.

The post Updates in cervical cancer appeared first on VJOncology.

Resistance to immune checkpoint inhibitors in NSCLC Jan 13, 2023

Show notes

In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell lung cancer (NSCLC). We’ll be hearing from Professor Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, Dr Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, and Dr Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, about new developments in our understanding of mechanisms of resistance, as well as possible therapeutic options for overcoming resistance.

The post Resistance to immune checkpoint inhibitors in NSCLC appeared first on VJOncology.

Impact of race on breast cancer outcomes Jan 06, 2023

Show notes

Breast cancer is one of the leading causes of cancer mortality, with incidence, pathology, and clinical outcomes varying by geographical distribution as well as different racial and ethnic populations. Black, compared to White women with localized breast cancer have higher mortality and worse distant recurrence-free survival, which is often attributed to social determinants of health and higher prevalence of triple-negative breast cancer in black patients. In addition, racial and ethnic diversity in breast cancer clinical trials is lacking with both Blacks and Hispanics underrepresented.

In this podcast, we hear from Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, Maja H. Oktay, MD, PhD, Montefiore Einstein Cancer Center, Bronx, NY, and Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, who discuss the impact of race on breast cancer outcomes, with respect to the RxPONDER trial, the role of the tumor microenvironment, as well as the impact of race on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with metastatic breast cancer.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post Impact of race on breast cancer outcomes appeared first on VJOncology.

Immunotherapy updates in GI cancer Dec 23, 2022

Show notes

Gastrointestinal (GI) cancers have a high incidence rate and is the leading cause of cancer-related mortality. Despite current combinational treatment strategies including chemotherapy, surgery, radiotherapy, and targeted therapies, survival rates remain markedly low for patients with advanced disease due to treatment resistance, rapid disease progression and metastasis, creating a strong urgency for the development of optimal therapeutic approaches. Immunotherapy is becoming increasingly established in the integrative management of GI cancers, with novel combinational strategies revolutionizing the treatment landscape and providing promise for patients with advanced stage disease.

In this podcast we hear from Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, Michael Overman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Andras Heczey, MD, Baylor College of Medicine, Houston, TX, and Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, on some of the latest immunotherapeutic strategies for treating GI cancers.

The post Immunotherapy updates in GI cancer appeared first on VJOncology.

Updates from ESMO Asia 2022 Dec 16, 2022

Show notes

The ESMO Asia 2022 congress took place on the 2nd to the 4th of December in Singapore. We heard from experts across Asia and Europe as they discussed the latest updates in oncology in the Asia-Pacific region.

In this episode, we hear from Dr Tomohiro Matsuda on the epidemiology of rare cancers in Asia, Dr Avinash Khadela and Dr Annalisa Trama on how to improve outcomes for patients with head and neck cancer, and Dr Kohei Shitara, Dr Ken Kato, and Dr Teresa Macarulla on updates in gastrointestinal cancers.

The post Updates from ESMO Asia 2022 appeared first on VJOncology.

Updates in EGFR-mutant NSCLC Dec 02, 2022

Show notes

A large proportion of patients with non-small cell lung cancer (NSCLC) have mutations in EGFR, making it a popular target for novel therapeutics. In this podcast, we hear from Prof. Charles Swanton, Dr Emilia Lim, Prof. Sanjay Popat, Dr Qing Zhou, Dr Hazel O’Sullivan, Dr Julia Rotow, and Dr Biagio Ricciuti, as they discuss some of the latest clinical trial data in this field, as well as perspectives on molecular testing and new research into the causes of EGFR-mutant lung cancer.

The post Updates in EGFR-mutant NSCLC appeared first on VJOncology.

UKONS 2022: cancer care in the digital age Nov 25, 2022

Show notes

The UKONS Annual Conference took place on 11^th and 12th November 2022 in Belfast, Ireland. Leading experts gave updates on the latest challenges in oncology nursing, with discussion around the conference theme ‘cancer care in the digital age’.

In this podcast, we hear from UKONS President Mark Foulkes (Royal Berkshire NHS Foundation Trust) with an overview of the UKONS 2022 debate on in-person versus virtual consultations. We also speak with experts Catherine Oakley (Guys and St Thomas NHS Foundation Trust) and Jo Armes (University of Surrey) who give interesting perspectives on the impact of digital innovations in oncology nursing and hazardous occupational exposure to cytotoxic drugs.

This podcast was recorded during the UK Oncology Nursing Society (2022) Annual Meeting held in Belfast, UK.

The post UKONS 2022: cancer care in the digital age appeared first on VJOncology.

Updates in immunotherapy from SITC 2022 Nov 18, 2022

Show notes

The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8^th-12^th of November 2022 in Boston, MA. Leading experts discussed practice-changing trial updates and the latest news in immune-oncology.

In this podcast, we hear from Prof. Judith Varner (University of California, San Diego, CA) on the combination of myeloid cell and T-cell targeting as an effective anti-tumor strategy and Dr Saman Maleki (Western University, London, Canada) on microbiome modification with fecal transplant before immunotherapy to reduce primary resistance in melanoma. We also hear exciting clinical trial updates in microsatellite stable colorectal cancer (MSS CRC) from Prof. Michael Overman (The University of Texas MD Anderson Cancer Center, Houston, TX) and in melanoma from Dr Diwakar Davar (UPMC Hillman Cancer Center, Pittsburgh, PA).

The post Updates in immunotherapy from SITC 2022 appeared first on VJOncology.

Advances in radiotherapy from ASTRO 2022 Nov 16, 2022

Show notes

The ASTRO 2022 Annual Meeting took place on the 23-26^th October 2022, in San Antonio, TX. Leading experts gave updates on clinical trials in radiotherapy, as well as discussing hot topics in the field.

In this podcast, we hear from several experts in the field of radiotherapy as they update us on the biggest trials and points of discussion presented at ASTRO 2022, including results from the CALLA trial (NCT03830866), unmet needs and challenges in radiotherapy, and thoughts on how artificial intelligence can be used to advance cancer care.

The post Advances in radiotherapy from ASTRO 2022 appeared first on VJOncology.

Immunotherapy Updates in Head & Neck Cancer Nov 04, 2022

Show notes

Head and neck squamous cell carcinoma (HNSCC) is the most prevalent form of head and neck cancer and is typically associated with tobacco use and the human papillomavirus (HPV). Whilst this form of cancer has historically been associated with poor prognosis, the advent of checkpoint inhibitors such as pembrolizumab has increased overall survival in patients with PD-L1–expressing HNSCC.

In this podcast, we will hear from Marcin Dzienis, MD, Gold Coast University Hospital, Southport, Australia, Jean-Pascal Machiels, MD, PhD, Cliniques Universitaires Saint-Luc, Brussels, Belgium, and Denis Soulieres, The Université de Montréal, Montréal, Canada, sharing their expert insights in this exciting field and the latest updates in the KEYNOTE-412 and KEYNOTE-B10 trials.

The post Immunotherapy Updates in Head & Neck Cancer appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected